Larimar Therapeutics Inc.
LRMR
We are a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using our novel cell penetrating peptide ( CPP ) technology platform. Our lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver frataxin ( FXN ), an essential protein, to the mitochondria of patients with…
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$156M
▼ -105.5% YoY
Op. Margin
–
ROIC
-106.06%
▼ -50.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$158M
▼ -59.0% YoY
Op. Cash Flow (TTM)
-$158M
▼ -60.0% YoY
Net Debt
-$124M
Net Cash Position
Cash & Equiv.
$129M
Continue Research
Peers
Pharmaceutical Preparations · Pick stocks to compare with LRMR
Held by ETFs
LRMR is in 13 US ETFs. The largest of them, with LRMR's weight in each:
Larimar Therapeutics (LRMR) in three numbers
Questions about Larimar Therapeutics
Is Larimar Therapeutics a high-quality business?
Larimar Therapeutics scores 10 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$124M, and its weakest is return on capital at -106.1%. The Quality tab shows every check against its target.
Does Larimar Therapeutics (LRMR) pay a dividend?
No. Larimar Therapeutics (LRMR) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 10 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in LRMR's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing LRMR
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.